No hay productos en el carrito



Encyclopedia of Drug Metabolism and Interactions, 6 Vols.
Lyubimov, A.
1ª Edición Diciembre 2012
Inglés
Tapa dura
3248 pags
5000 gr
null x null x null cm
ISBN 9780470450154
Editorial WILEY
LIBRO IMPRESO
-5%
2056,41 €1953,59 €IVA incluido
1977,32 €1878,45 €IVA no incluido
Recíbelo en un plazo de
2 - 3 semanas
Description
The Encyclopedia of Drug Metabolism and Interactions provides essential support during all phases of drug development, from drug design to drug action and interaction in patients.
This multivolume work covers both preclinical and clinical aspects of drug metabolism and interactions. It also provides a wealth of toxicological, regulatory, and marketing information, all written by leading international experts in the field. Using this reference you’ll discover:
- Enzymes that can be inhibited or induced and their impact on drug toxicity and altered response in both animal and human models
- Effect of genetic differences and non-genetic factors on drug metabolism
- Balance among drug metabolism, its inactivation/activation, and its potential toxicity
- Examples demonstrating all aspects of drug metabolism and interactions in silico, in laboratory animals, and in humans
- Methods and detailed protocols enabling you to perform seamless studies of metabolism and drug interactions.
This reference is essential for researchers interested in all aspects of drug development, and chemists, pharmacologists, pharmaceutical specialists, toxicologists, molecular toxicologists, and clinicians, including practitioners and physicians.
Table of Contents
VOLUME I
- Part 1: Basics Overview of Drug Metabolism
- Chapter 1 Review of Drug Metabolism in Drug Discovery and Development
- Chapter 2 Reactions and Models of Drug Metabolism
- Chapter 3 Enzyme kinetics of drug metabolism reactions and drug-drug interactions
- Chapter 4 Developmental changes in drug metabolizing enzymes
- Chapter 5 Species differences in drug metabolizing enzymes
- Part II: Enzyme systems involved in drug metabolism and interactions in animals and humans
- Chapter 6 Structure and function of cytochrome P450 enzymes
- Chapter 7 Mechanism of cytochrome P450 mediated reactions
- Chapter 8 Transcriptional regulation of cytochrome P450 enzymes
- Chapter 9 Cytochrome P450 polymorphisms
- Chapter 10 Flavin monooxygenase
- Chapter 11 Molybdenum containing enzymes
- Chapter 12 Amine odidases and reductases
- Chapter 13 Epoxide hydrolase
- Chapter 14 Esterases and amidases
- Chapter 15 UDP- glucuronosyltransferases
- Chapter 16 Sulfotransferases
- Chapter 17 Glutathione S- transferases
- Chapter 18 Amino acid conjugation
VOLUME II
- Part III: General principals of ADME. Drug transporters and other mechanisms of transport
- Chapter 1 Introduction to ADME. Overview
- Chapter 2 Anatomical and Physiological Parameters that Influence Gastrointestinal Absorption
- Chapter 3 Absorption of drugs into the body
- Chapter 4 General principles of drug distribution
- Chapter 5 ABC drug transporters and their impact on drug disposition/drug sensitivity and resistance
- Chapter 6 SLC family transporters
- Chapter 7 General principles of drug metabolism
- Chapter 8 Systems where drug metabolism occurs
- Chapter 9 Mass balance studies in animals and humans
- Chapter 10 Bioavailability and bioequivalence
- Chapter 11 Allometric scaling
- Chapter 12 Effect of protein binding in ADME
- Chapter 13 Excretion systems
- Chapter 14 Pharmacokinetics (PK) and toxicokinetics (TK)
- Chapter 15 Experimental design/mathematical models and data analysis/interpretation for PK /TK studies
- Chapter 16 Physiologically-Based Pharmacokinetic Modeling
- Chapter 17 Pharmacodynamics
- Chapter 18 Interrelationships between Pharmacokinetics / Pharmacodynamics and metabolism
- Part IV: ADME of some specific groups of drugs and delivery systems
- Chapter 19 ADME of herbal and dietary constituents
- Chapter 20 ADME of anticancer drugs
- Chapter 21 ADME of cardiovascular drugs
- Chapter 22 ADME of biological drugs
- Chapter 23 ADME of natural toxins
- Chapter 24 Metabolism and drug-drug interactions in pregnant mother/placenta/fetus
VOLUME III
- Part V: Drug Design and development
- Chapter 1 Where and when does drug metabolism enter as a concern?
- Chapter 2 Challenges in frontloading toxicity testing of anti- cancer drugs in drug discovery
- Chapter 3 Role of ADME for selection of new drug candidates
- Chapter 4 Efficient drug development. How to speed up the development process
- Chapter 5 Metabolite profiling and identification
- Chapter 6 Bioactivation and oxidative stress
- Chapter 7 Metabolism in drug safety evaluation
- Part VI: Methods and protocols for prediction and evaluation of drug metabolism and drug interaction studies
- Chapter 8 In silico models of drug metabolism and drug interactions
- Chapter 9 Methods for determination of enzyme kinetics and metabolic rates
- Chapter 10 Assays and microarrays for metabolic pathways
- Chapter 11 Applications using Caco-2 cells and TC7 cells for drug metabolism studies
- Chapter 12 In vitro liver systems to study induction/inhibition. Prediction of in vivo metabolism and drug-drug interactions
- Chapter 13 Assessing the Hepatic Disposition and Toxicity of Xenobiotics Using Primary Hepatocytes
- Chapter 14 Monoclonal Antibody Based Analyses of Human Drug Metabolism and Multifuctional Cytochromes P450
- Chapter 15 Validation of precision- cut slices as a tool to study induction of drug metabolism
- Chapter 16 Practical aspects of high throughput solubility and dissolution assessment in preformulation
- Chapter 17 Integrated Approaches to Blood Brain Barrier and its role for drug metabolism and interactions
- Chapter 18 In vivo models (not genetically modified)
- Chapter 19 Using mouse knockout and transgenic models to study metabolism
VOLUME IV
- Part VII: Pharmacology and toxicology
- Chapter 1 Introduction. Overview. Role of metabolism in drug toxicity
- Chapter 2 Bioactivation I: Phase I (P450)
- Chapter 3 Bioactivation II: Phase I (non P450)
- Chapter 4 Bioactivation III: Phase II
- Chapter 5 Covalent Binding
- Chapter 6 MIST
- Chapter 7 Cell- based predictors for Toxicities of Metabolites
- Chapter 8 Toxicogenomics
- Chapter 9 Metabonomics
- Chapter 10 Proteomics
- Chapter 11 Stereoselectivity in drug metabolism
- Part VIII: Influence of physiological conditions, diseases, drug- food interactions, age, sex, and other factors on drug metabolism and effect
- Chapter 12 Genetic influence on metabolism
- Chapter 13 Drug- Drug interactions 1: Inhibition
- Chapter 14 Drug- Drug Interactions 2: Induction
- Chapter 15 Ontogeny and Metabolism
- Chapter 16 Natural Modulators of Human Drug Metabolism: Dietary supplements and their Clinical Relevance (Food Effects on Toxicity and Pharmacology)
- Chapter 17 Idiosyncratic drug interactions
- Chapter 18 Influence of inflammatory stress on drug (or xenobiotic) hepatotoxicity
- Chapter 19 Regulation of Drug-Metabolizingnzymes and Transporters in Infection, Inflammation, and Cancer
VOLUME V
- Part IX: Bioanalytical methods of studying metabolism
- Chapter 1 Introduction. Importance of in vivo/in vitro analytical results in drug development Walter
- Chapter 2 General principles of mass spectrometry: LC-MS, LC-MS/MS, and GC-MS
- Chapter 3 Electrospray and Infusion nanospray ionization
- Chapter 4 Emerging Atmospheric pressure ionization
- Chapter 5 Matrix assisted laser desorption ionization (MALDI)
- Chapter 6 Ion trap and quadrupole MS
- Chapter 7 Hybrid LTQ- FTMS for Drug Metabolism Applications
- Chapter 8 Mass Spectrometry Imaging (MSI)
- Chapter 9 Ion Mobility Spectrometry and High Performance Tandem MS for metabolism studies and identification
- Chapter 10 Inductively coupled plasma mass spectrometry (ICP MS) for element- containing drug metabolism analysis
- Chapter 11 Online Electrochemical LC- MS Techniques for Profiling
- Chapter 12 NMR
- Chapter 13 Whole body autography and radioactive and non- radioactive isotope assays
- Chapter 14 Ligand binding assays (immunoassays)
- Chapter 16 Direct plasma analysis systems
- Chapter 17 Analytical method development and validation in accordance to the regulatory guidelines
- Chapter 18 Leveraging advances in HPLC to maximize DMPK data quality
- Chapter 19 Methodologies to Increase Analytical Throughput
- Chapter 20 Biomarkers to enable PK/PD
- Chapter 21 Bioanalytics for Human Microdosing
- Chapter 22 Bioactivation and Reactive Metabolite Assays
- Chapter 23 Plasma protein binding
VOLUME VI
- Part X: Clinical aspects of drug metabolism and interactions
- Chapter 1 Overview and introduction. Role of drug metabolism and drug interactions in humans
- Chapter 2 Human cytochrome P450 enzymes
- Chapter 3 DDI Risk Assessment and Evaluation in Clinical Development: Interfacing Drug Metabolism and Clinical Pharmacology
- Chapter 4 Current and future tools for predicting clinical drug interactions
- Chapter 5 Predicting human biotransformation pathways
- Chapter 6 Conjugation, transport, and elimination of drugs in humans
- Chapter 7 Role and clinical consequences of human UDP- Glucuronosyltransferases
- Chapter 8 Drug/food and drug/herb interactions
- Chapter 9 Effects of disease on metabolism of drugs in humans
- Chapter 10 Role of Phase I metabolism in drug activation and clinical treatment outcomes
- Chapter 11 Role of metabolism in toxicity of drugs in humans
- Chapter 12 Idiosyncratic drug reactions and the potential role of metabolism
- Part XI Metabolism of specific drug groups and patient populations
- Chapter 13 Metabolism of psychotropic drugs
- Chapter 14 Metabolic-based consequences of polytherapy with AED
- Chapter 15 Oral chemotherapeutic agents: Understanding mechanisms of action and drug interactions
- Chapter 16 Drug metabolism and interactions in pediatric patients
- Chapter 17 Population- based pharmacokinetic modeling and simulation
- Chapter 18 Clinical Pharmacology in drug labeling. The impact of drug metabolism and clinical pharmacology on recommended dose of drugs
© 2025 Axón Librería S.L.
2.149.0